Pfizer Ventures backs effort to amp up orphan-drug development

Tracy Staton David Mott, ex-CEO of MedImmune and a high-profile biotech partner at New Enterprise Associates, has led the way toward an orphan drug accelerator also backed by Pfizer ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS